N. Lapointe et al., Immunomodulating effects of second-generation calcium channel blockers on experimental heart transplantation, EUR SURG RE, 31(3), 1999, pp. 259-266
The administration of second-generation calcium channel blockers (CCBs) to
counteract the adverse effects of conventional immunosuppression gains more
and more acceptance. Since these newly developed molecules differ in their
chemical structure and possess specific pharmacokinetic profiles, we hypot
hesized that exposure to clinically relevant concentrations may have a sign
ificant immunomodulatory potential. The effects of various second-generatio
n CCBs, felodipine, amlodipine, mibefradil and clentiazem, on cardiac allog
raft survival were therefore evaluated. Inbred male Lewis rats were used as
recipients and Brown-Norway rats as donors. After abdominal implantation o
f the donor heart, allograft recipients were exposed to felodipine (31 mu g
/kg/day), amlodipine (25 mu g/kg/day), mibefradil (3 mg/kg/day) or clentiaz
em (2.5 mg/kg/day). Other a I log raft recipients were treated with low-dos
e cyclosporine (CsA) alone (2 mg/kg/day) or with low-dose CsA combined with
amlodipine (25 mu g/kg/day), mibefradil (3 mg/kg/day) or clentiazem (2.5 m
g/kg/day). All drugs were given daily by gavage. Median survival time of un
treated cardiac allografts was 6.5 days. When given alone, not all the seco
nd-generation CCBs elicited a positive effect: the dihydropyridines felodip
ine and amlodipine were ineffective (median survival time was 6.5 and 7.0 d
ays, respectively), the T- and L-type CCB mibefradil had a significant but
minor impact (median survival time = 9.0 days, p <0.0015) while the benzoth
iazepine clentiazem produced the most significant result (median survival t
ime = 16.0 days, p <0.0033). Neither amlodipine nor mibefradil modified the
extent of survival provided by low-dose CsA (median survival time = 9.0 da
ys), while clentiazem had a significant positive effect. These data indicat
e that second-generation CCBs differ in their immunomodulatory potential. T
hese observations of pharmacodynamic specificity appear to be related to di
fferences in their chemical structure as well as their interaction with oth
er sites than the calcium channel.